Addeo A - Search Results

1

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

Mogavero A, Cantale O, Mollica V, Anpalakhan S, Addeo A, Mountzios G, Friedlaender A, Kanesvaran R, Novello S, Banna GL. Mogavero A, et al. Among authors: addeo a. Expert Rev Respir Med. 2023 Dec;17(12):1191-1206. doi: 10.1080/17476348.2024.2302356. Epub 2024 Feb 9. Expert Rev Respir Med. 2023. PMID: 38294292 Review.

2

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Addeo A, et al. Crit Rev Oncol Hematol. 2018 Feb;122:150-156. doi: 10.1016/j.critrevonc.2017.12.015. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458783 Free article. Review.

3

Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.

Addeo A, Banna G. Addeo A, et al. Eur Respir J. 2018 Apr 4;51(4):1800084. doi: 10.1183/13993003.00084-2018. Print 2018 Apr. Eur Respir J. 2018. PMID: 29618603 Free article. No abstract available.

4

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.

Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zanghì G, Lal R, Libra M. Banna GL, et al. Among authors: addeo a. Anticancer Res. 2018 Jun;38(6):3689-3697. doi: 10.21873/anticanres.12647. Anticancer Res. 2018. PMID: 29848729 Clinical Trial.

5

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Banna GL, et al. Among authors: addeo a. Crit Rev Oncol Hematol. 2018 Sep;129:27-39. doi: 10.1016/j.critrevonc.2018.06.016. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097235 Review.

6

Atezolizumab Treatment of Nonsquamous NSCLC.

Mountzios G, Calles A, Addeo A. Mountzios G, et al. Among authors: addeo a. N Engl J Med. 2018 Sep 20;379(12):1187. doi: 10.1056/NEJMc1809195. N Engl J Med. 2018. PMID: 30260156 No abstract available.

7

The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

Addeo A, Banna GL. Addeo A, et al. J Thorac Dis. 2018 Sep;10(Suppl 26):S3305-S3307. doi: 10.21037/jtd.2018.08.95. J Thorac Dis. 2018. PMID: 30370144 Free PMC article. No abstract available.

8

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S283-S286. doi: 10.21037/tlcr.2018.07.10. Transl Lung Cancer Res. 2018. PMID: 30393623 Free PMC article. No abstract available.

9

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S287-S289. doi: 10.21037/tlcr.2018.07.09. Transl Lung Cancer Res. 2018. PMID: 30393624 Free PMC article. No abstract available.

10

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Addeo A, et al. Crit Rev Oncol Hematol. 2019 Jul;139:158. doi: 10.1016/j.critrevonc.2018.06.018. Epub 2018 Nov 2. Crit Rev Oncol Hematol. 2019. PMID: 30396775 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

214 results

Search Page